Inside Atossa Therapeutics (Nasdaq: ATOS): CEO Dr. Steven Quay on Advancing Breast Cancer Treatment

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is prioritizing metastatic breast cancer, a setting with limited effective therapies and high unmet need, where (Z)-endoxifen has demonstrated encouraging clinical activity and favorable tolerability. This focus may enable a more efficient regulatory pathway while building a foundation for expansion into prevention, neoadjuvant, and adjuvant settings. With multiple ongoing Phase 2 trials, a proprietary oral formulation, and a strong intellectual property portfolio, Atossa is positioned to deliver meaningful therapeutic innovation and create long-term value for patients and investors alike.Visit RedChip.com to learn more.